14. Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) Patients and methods: We identified 636 men treated for IR-PrCa with DE-RT (>75Gy). The adult comorbidity evaluation-27 index classifed comorbidity. Kaplan-Meier and log-rank tests compared failure-free survival (FFS) with and without ADT.
ratio 0.36; P = 0.004). Recursive partitioning analysis of men without ADT classified Gleason 4 + 3 = 7 or ≥50% positive cores as unfavorable disease. The addition of ADT to DE-RT improved 5-year FFS for men with unfavorable disease (81.6% versus 92.9%; P = 0.009) but did not improve FFS for men with favorable disease (96.3% versus 97.4%; P = 0.874). When stratified by comorbidity, ADT improved FFS for men with unfavorable disease and no or mild comorbidity (P = 0.006) but did not improve FFS for men with unfavorable disease and moderate or severe comorbidity (P = 0.380). [6, 7] , and Dana Farber Cancer Institute (DFCI) [8] trials reported an improvement in both disease control and survival with the addition of short-term ADT (4-6 months) to standard-dose EBRT of 66-70 Gy.
Conclusion:
While randomized trials have demonstrated an improvement in disease control with the use of DE EBRT compared with standard-dose EBRT and a survival advantage with the use of short-term ADT in conjunction with standard-dose EBRT compared with standard-dose EBRT alone, the incremental benefit of adding short-term ADT to DE EBRT is uncertain. Although the addition of short-term ADT may improve prostate cancer outcomes, it can cause also significant sideeffects including fatigue, hot flashes, loss of libido, endocrine abnormalities, decreased bone density, and possibly cardiovascular complications.
The ongoing RTOG 08-15 randomized trial will provide level 1 evidence on the effect of adding short-term ADT to DE radiation therapy (RT), but the results will not be available for several years. Therefore to determine the incremental benefit of adding short-term ADT to DE EBRT, we analyzed men with IR-PrCa treated at MD Anderson with DE EBRT (>75 Gy) with or without short-term ADT. Additionally, we identified a subgroup of men most likely to benefit from the addition of ADT based on patient and disease characteristics. [9] . All men received at least 75 Gy to the prostate; either 75.6 Gy prescribed to the planning target volume or 78 Gy prescribed to the isocenter, delivered in 1.8 or 2 Gy fractions. Lymph nodes were not treated. ADT was administered based on physician's recommendation and patient preference. ADT consisted of a gonadotropin-releasing hormone analog with or without an anti-androgen. Generally, RT was administered over ∼8 weeks and ADT treatment was given before, during, and after RT with completion of ADT ∼2 months after the completion of radiation treatment. The study was conducted with approval from the institutional review board. We excluded men with Gleason combined score <6, Gleason 7 cancers without score breakdown (3 + 4 versus 4 + 3) and no information to calculate percent positive biopsy cores. The remaining 636 men comprised the study cohort.
primary outcome
The primary outcome was failure-free survival (FFS), with failure defined as PSA ≥2 ng/ml above the nadir, administration of salvage therapy for progressive disease, or radiographic or pathological evidence of local, nodal, or distant recurrence. FFS was calculated from the end of radiation treatment.
explanatory covariates
Severity of comorbid conditions at time of radiation oncology consultation was assessed using the adult comorbidity evaluation-27 (ACE-27). The ACE-27 index was selected because it is validated for patients with newly diagnosed cancer as an independent predictor of survival [10] . The ACE-27 classifies specific ailments into four comorbidity levels: grade 0, no comorbidity; grade 1, minimal; grade 2, moderate; and grade 3, severe. Overall comorbidity score is defined based on highest ranked single ailment, except when two moderate ailments occur in different organ systems. If that occurs, the overall score is designated severe. The ACE-27 grade was assigned for all men by one author (SXB) and confirmed by independent assessment (KEH) for 5% of the cohort.
The Gleason score was established based on pathology review at MD Anderson by a pathologist with expertise in genitourinary pathology. Gleason score was categorized as 6, 3 + 4 = 7, or 4 + 3 = 7. The proportion of involved biopsy cores was calculated by dividing the number of involved cores by the number of evaluated cores and categorized as <50% or at least 50%. T stage was categorized as T1 or T2. PSA was categorized as <10 or 10-20 ng/ml. Men were categorized as having received or not having received ADT. Descriptive statistics were generated for the study cohort. Analyses were conducted in SAS 9.2 or STATA 11 unless otherwise specified [11, 12] . Chi-square and Kruskal-Walllis tests compared men who did and did not receive ADT. The impact of patient, tumor, and treatment characteristics on FFS was examined using univariate and multivariate Cox proportional hazard regression models. The independent association of ADT administration on FFS was first evaluated in a multivariate model that assessed all explanatory variables (T stage, Gleason score, percent positive cores, PSA, comorbidity, and ADT administration) and selected covariates for inclusion by backward elimination. Subsequently, a multivariate model was constructed that included all explanatory variables without elimination. Since conclusions were the same, results of the model including all variables are reported. Hazard ratios (HRs) and adjusted HR (AHR) are presented with 95% confidence intervals (CIs). P value <0.05 was considered statistically significant.
defining an unfavorable subgroup
Recursive partioning analysis was applied using the rpart routine in the R programming language to separate patients into similar groups with respect to risk of PSA failure [13, 14] . Gleason Score, PSA, at least 50% core involvement, T stage, overall comorbidities, and cardiovascular comorbidities were entered as potential explanatory variables. For this time to event analysis, the rpart routine grouped patients with similar values for the martingale residual from a null Cox model.
Kaplan-Meier survival estimates
Kaplan-Meier survival estimates were constructed to determine 5-year FFS for the entire cohort and for subgroups of patients. Patients were stratified by ADT administration and log-rank tests assessed the impact of ADT on FFS.
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On multivariate analysis ( Table 2 ) that adjusted for differences in comorbidities, T stage, Gleason score, and percent positive cores, men who received ADT in addition to DE EBRT had improved FFS compared with men who did not receive ADT (AHR 0.36, 95% CI 0.18-0.72; P = 0.004). After adjustment for other factors, men with at least 50% positive cores had inferior FFS compared with men with <50% positive cores (AHR 2.43, 95% CI 1.28-4.63; P = 0.007). Additionally, men with Gleason 4 + 3 = 7 disease had worse FFS than men with Gleason 6 disease (AHR 6.70, 95% CI 1.45-31.0; P = 0.015).
defining an unfavorable subgroup of patients
Recursive partitioning analysis of men who did not receive ADT identified the subgroup of men with unfavorable disease.
Men with Gleason 4 + 3 = 7 disease or at least 50% positive cores were more likely to fail. Therefore, men with Gleason 4 + 3 = 7 disease or at least 50% positive cores were classified as having unfavorable disease. The remaining men were classified as having favorable disease. Kaplan-Meier curves for men not receiving ADT were constructed; 5-year FFS rates were 96.3% (95% CI 91.4% to 98.5%) for men with favorable disease and 81.6% (95% CI 72.3% to 88.1%) for men with unfavorable disease (P < 0.001), confirming our definitions (Figure 1 ).
incremental benefit of adding ADT to DE EBRT for subgroups of patients
An analysis of the 334 patients with unfavorable disease showed the addition of short-term ADT to DE EBRT improved disease control compared with DE EBRT alone (Figure 2A ). The addition of ADT improved 5-year FFS from 81.6% (95% CI 72.3% to 88.1%) to 92.9% (95% CI 85.8% to 96.5%) (P = 0.009). This benefit was not seen among the 302 men with favorable disease. Five-year FFS was 96.3% (95% CI 91.4% to 98.5%) without ADT and 97.4% (95% CI 92.3% to 99.2%) with ADT ( Figure 2B , P = 0.874).
We stratified patients based on severity of comorbidites into those with no or minimal comorbidity (ACE-27 score 0 or 1) and those with moderate to severe comorbidity (ACE-27 score 2 or 3). Among the 235 men with unfavorable disease and no or minimal comoribidity, the addition of ADT to DE EBRT significantly improved 5-year FFS from 84.3% (95% CI 73.9% to 90.8%) to 95.5% (95% CI 87.9% to 98.4%) ( Figure 3A , P = 0.006). Among the 99 men with unfavorable disease and moderate to severe comoribidity, the addition of ADT to DE EBRT numerically improved 5-year FFS from 74.1% (95% CI 50.9% to 87.6%) to 87.9% (95% CI 70.7% to 95.4%) but ADT, androgen deprivation therapy; CI, confidence interval; PSA, prostate-specific antigen. P-values presented in bold are statistically significant.
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analysis had limited numbers, the survival curves converged, and the difference was not statistically significant ( Figure 3B , P = 0.380). Among the 223 men with favorable disease and no or minimal comoribidity, the addition of ADT to DE EBRT did not significantly improve 5-year FFS. Five-year FFS was 95.3% (95% CI 89.0% to 98.0%) without ADT and 98.8% (95% CI 91.9% to 99.8%) with ADT (P = 0.263). Similarly, among the 79 men with favorable disease and moderate to severe comoribidity, the addition of ADT to DE EBRT did not improve 5-year FFS. Five-year FFS was 100% (95% CI undefined) without ADT and 93.9% (95% CI 77.7% to 98.4%) with ADT (P = 0.115).
discussion
Our results demonstrate the addition of short-term ADT to DE EBRT improves FFS for men with unfavorable IR-PrCa (Gleason 4 + 3 = 7 disease or involvement of at least half of the biopsy cores). This benefit was specifically seen among men with unfavorable disease and no or minimal comorbidities. It is not clear if this benefit extends to men with unfavorable disease and moderate to severe comorbidities due to the limited number of men with these characteristics in our study.
Our results suggest men with favorable intermediate-risk disease may not benefit from the addition of short-term ADT to DE EBRT. Radiation dose escalation and short-term ADT have both been shown independently to improve prostate cancer outcomes over standard-dose EBRT alone. Three randomized trials that included men with IR-PrCa demonstrated a benefit from radiation dose escalation over standard-dose radiation. A trial of 301 patients at MD Anderson concluded that 78 Gy EBRT decreases biochemical failure compared with 70 Gy EBRT [1, 2] . A trial of 393 men conducted at Massachusetts General Hospital and Loma Linda showed a biochemical disease-free survival benefit from dose escalation to 79 Gy compared with 70 Gy [4] . Additionally, a Dutch trial of 664 men reported improved freedom from failure with 78 Gy compared with 68 Gy [3] . Similarly, three randomized trials that included men with IR-PrCa have demonstrated a benefit from the addition of short-term ADT to standard-dose EBRT. DFCI reported improvement in overall survival and diseasefree survival with the addition of 6 months of ADT to 70 Gy EBRT [8] . RTOG 94-08 demonstrated overall survival and disease-specific survival benefits with the addition of 4 months of ADT to 67 Gy EBRT [5] . Furthermore, the TROG showed original articles Annals of Oncology improvement in disease-free survival and prostate cancerspecific survival with the addition of 6 months of ADT to 66 Gy EBRT [6] .
However, there is limited data on the benefit of combining ADT with DE EBRT. While the MRC RT01 randomized trial showed improvement in progression-free survival when DE EBRT (74 Gy) was combined with ADT compared with lower dose EBRT (64 Gy) combined with ADT, the study does not provide insight as to whether there is an incremental benefit from adding ADT to DE EBRT. In contrast to our finding that the addition of ADT to DE EBRT improved FFS for men with IR-PrCa, a reanalysis of 292 men enrolled in the RTOG 94-06 trial, initially designed to assess maximum-tolerated radiation dose, did not show a benefit from the addition of ADT to DE EBRT [15] . Additionally, in a retrospective analysis by Zelefsky et al. [16] , ADT did not improve biochemical control for men with IR-PrCa in a multivariate analysis that included the effects of dose escalation. In both the reanalysis of RTOG 94-06 and the Zelefsky retrospective analysis, the authors may not have seen a benefit from the addition of ADT because they did not adjust for potential imbalances in adverse features between the two groups due to differences in the proportion of men with Gleason 4 + 3 = 7 disease and proportion of men with at least 50% positive cores.
The population of men with IR-PrCa is a heterogeneous group. Through characterization of favorable and unfavorable subsets of disease and assessment of differences in comorbid conditions, we identified a group of men most likely to benefit from the addition of ADT to DE EBRT. The two criteria identified for inclusion in our unfavorable subgroup, Gleason 4 + 3 = 7 disease or at least 50% positive biopsy cores, have been linked with inferior prostate cancer outcomes in other studies. Gleason score breakdown of 4 + 3 = 7 has been correlated with increased prostate cancer death compared with a breakdown of 3 + 4 = 7 in several studies [9, 17] . Likewise, retrospective analyses have shown that a greater percentage of positive cores is an independent predictor of biochemical failure in men with intermediate-risk disease [18] [19] [20] .
Our results demonstrate the addition of short-term ADT to DE EBRT improves FFS for men with unfavorable IR-PrCa. The improvement is clinically significant, with a 10% absolute improvement in 5-year FFS. It is equally important to identify subgroups of men for whom ADT does not provide a benefit. ADT is not a benign treatment and can cause fatigue, decreased libido, and hot flashes in addition to less common side-effects such as weight gain, decreased muscle mass, increased lipid levels, and decreased bone density. Additionally, ADT may exacerbate comorbid conditions like diabetes and cardiovascular disease [21] . These side-effects can negatively impact a patient's quality of life. Therefore, it is important to omit ADT when it does not improve cancer outcomes. Our results suggest men with favorable IR-PrCa may not benefit from ADT and therefore can be spared of the unnecessary side-effects of ADT.
When comorbid conditions were taken into account, the benefit of adding ADT to DE EBRT was specifically seen among men with unfavorable disease and no or minimal comorbidities. Consistent with our finding, reanalysis of the DFCI randomized trial showed the addition of ADT to standard-dose EBRT improved overall survival among the intermediate-risk patients with low comorbidity scores [22, 23] . In the DFCI analysis, the improvement was not seen in men with high comorbidity scores. In our study, it is not clear whether men with unfavorable disease and moderate to severe comorbidities benefit from the addition of ADT due to the limited number of men with these characteristics in our study. It is postulated patients with severe comorbidities may not benefit from the addition ADT because of competing risks of death from non-prostate cancer causes and because they may be more likely to experience the detrimental endocrine and cardiovascular effects of ADT.
A few points deserve further consideration. This study was a retrospective analysis; therefore, the results can suggest an association but cannot definitely determine causation. The length of follow-up was limited; however, the length was similar to follow-up reported in initial publications from several trials establishing the superiority of DE EBRT and the benefit of ADT to standard-dose EBRT [2-4, 6, 8] . While median duration of ADT was 6 months, the study was not designed to evaluate the optimal duration of ADT administration. Additionally, the number of death events was limited; therefore, we could assess the impact of ADT on FFS but could not assess the impact of adding ADT on overall survival or prostate cancer mortality. Longer follow-up of this cohort will be necessary to determine the impact of ADT on survival.
The ongoing RTOG 08-15 prospective randomized trial of DE radiotherapy with or without short-term ADT for patients with IR-PrCa will provide definitive level 1 evidence regarding the magnitude of the benefit of adding short-term ADT to DE EBRT. The study stratifies patients by severity of comorbid conditions (based on ACE-27) and by severity of disease. Therefore, RTOG 08-15 will also help determine which subsets of patients benefit most from the addition of ADT to DE radiotherapy. The trial is still enrolling patients and results are not expected for several years.
While we await the results of RTOG 08-15, data from retrospective studies can help guide clinical decisions and counsel patients, acknowledging the limitations of these studies. Our study concluded the addition of short-term ADT to DE EBRT improves FFS for men with unfavorable IR-PrCa (Gleason 4 + 3 = 7 disease or at least 50% involved cores). Therefore, short-term ADT should be discussed with men with unfavorable intermediate-risk disease who will be receiving DE EBRT. This benefit was specifically seen among men with unfavorable disease and no or minimal comorbidities. It is not clear if this benefit extends to men with unfavorable disease and moderate to severe comorbidities due to a limited number of men in our study with these characteristics. Our results also suggest men with favorable intermediate-risk disease may not benefit from the addition of short-term ADT to DE EBRT. Longer follow-up and results from RTOG 08-15 are needed to confirm our findings. disclosure
